1. A pharmaceutical preparation comprising (i) a human antibody that specifically binds to human nerve growth factor (hNGF)； (ii) a nonionic surfactant； and (iii) a carbohydrate. 2. The pharmaceutical preparation of claim 1, wherein the carbohydrate is sugar. The pharmaceutical preparation according to claim 2, wherein the sugar is selected from the group consisting of sucrose, glucose, mannitol, sorbitol, lactose and trehalose. The pharmaceutical preparation according to claim 3, wherein the sugar is sucrose. The pharmaceutical preparation according to claim 1, wherein the nonionic surfactant is selected from the group consisting of polysorbate 20, polysorbate 80 and polyoxyethylene sorbitan monooleate. The pharmaceutical preparation according to claim 5, wherein the non-ionic surfactant is polysorbate 20.7. The pharmaceutical preparation according to claim 6, further comprising at least one amino acid selected from the group consisting of histidine and arginine. The pharmaceutical preparation of claim 1, further comprising from about 1.0 mM to about 50 mM acetate. A pharmaceutical preparation comprising (i) approximately 0.1-100 mg / ml of a human antibody that specifically binds to hNGF； (ii) about 0.01-1.0% polysorbate 20； and (iii) about 1-20% sucrose. 10. The pharmaceutical preparation according to claim 9, comprising (i) approximately 0.2-75 mg / ml of a human antibody that specifically binds to hNGF； (ii) about 0.02-0.5% polysorbate 20； and (iii) about 5-10% sucrose. 11. The pharmaceutical preparation of claim 10, comprising (i) approximately 0.6-60 mg / ml of a human antibody that specifically binds to hNGF； (ii) approximately 0.05% polysorbate 20； and (iii) approximately 8% sugar�1. Фармацевтический препарат, включающий (i) антитело человека, которое специфически связывается с фактором роста нервов человека (hNGF)； (ii) неионное поверхностно-активное вещество и (iii) углевод.2. Фармацевтический препарат по п.1, в котором углеводом является сахар.3. Фармаце
